Trailblazing in the Arabian Desert: MyHeritage Sponsors Team Competing in 2021 Dakar Rally
5.1.2021 16:00:00 EET | Business Wire | Press release
MyHeritage, the leading global platform for discovering your past and empowering your future, announced today that it is sponsoring a racing team in the 2021 Dakar Rally — the elite off-road endurance competition currently taking place in Saudi Arabia. The MyHeritage team comprises driver Danny Pearl, a veteran of off-road racing, and navigator Charly Gotlib, who has participated in the Dakar Rally more than 30 times over the years, and has received an honorary distinction of Dakar Legend from the race organizers. The team is managed by Omer Pearl, Danny’s son. In recent years, Omer has managed the Pearl Racing Team in different competitions around the world. The team is named the MyHeritage Team and is competing in the Dakar’s Lightweight Vehicle category.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210105005542/en/
Trailblazing in the Arabian Desert: MyHeritage Sponsors Team Competing in 2021 Dakar Rally (Photo: Business Wire)
As the international market leader for exploring family history and finding relatives, MyHeritage develops innovative search and matching technologies and has a global database of historical records to help millions of people connect to their family history. Sponsoring a team led by a father-son duo is par for the course for MyHeritage. The company has a long history of partnering with top athletes, sports teams, and cultural figures to reveal their family history, forge connections with their relatives, and underscore the importance of knowing one’s roots.
Danny and Omer Pearl founded the Pearl Racing Team out of their passion for motorsports. The team has competed for many years in the SSV category, racing in numerous international competitions.
The Dakar Rally is considered the toughest and most grueling off-road competition in the world. This is the second year the competition is being held in Saudi Arabia, following its relocation from South America, where it was held for the last decade. The race spans more than 7,000 kilometers and 12 days over the challenging and beautiful Saudi terrain. This year’s race departed from Jeddah and will traverse the entire Arabian desert in a circular course. Each day the team will navigate under the most extreme conditions, using a Road Book produced by the rally organizer.
“As leaders in the field of exploring and discovering family history, we are thrilled to support a team that includes a father and son who are competing in one of the world’s most difficult competitions,” said Gilad Japhet, Founder and CEO of MyHeritage. “Particularly during these challenging times, we appreciate the significance of supporting family members coming together in bold and creative ways, working as a team to achieve the impossible. Just like the Dakar, family history can be an enjoyable and adventurous journey.”
“It is with great pride and excitement that we enter this legendary race,” said Omer Pearl. “We believe that determination and perseverance yield results, and our family bond is one of the driving forces behind our success. We hope that our efforts will inspire more families to team up and work together to pursue their dreams.”
The Dakar Rally is taking place between January 3–15, 2021.
About MyHeritage
MyHeritage is the leading global discovery platform for exploring family history. With billions of historical records and family tree profiles, and with sophisticated matching technologies that work across all its assets, MyHeritage allows users to discover their past and empower their future. Launched in 2016, MyHeritage DNA has become one of the world’s largest consumer DNA databases, with more than 4.6 million customers. Since 2020, MyHeritage is home to the world’s best technologies for enhancing and colorizing historical photos. MyHeritage is the most popular DNA test and family history service in Europe. www.myheritage.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210105005542/en/
Contact information
MyHeritage
Rafi Mendelsohn
Director of PR & Social Media
Phone: 917-725-5018
Email: pr@myheritage.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202630.8.2026 00:54:00 EEST | Press release
Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon company, in strategic partnership with the Emirates Falconers’ Club, at ADNEC Centre Abu Dhabi. The exhibition runs until 6 September. The falcon, owned
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom